摘要
目的:评价芪苈强心胶囊治疗慢性心力衰竭(CHF)的疗效及安全性。方法:检索2007-01至2017-03期间Pubmed、EMBASE、Web of Science、万方、维普、CBM、中国知网数据库,收集芪苈强心胶囊治疗CHF的研究。比较分析芪苈强心组及对照组B型利钠肽(BNP)、6分钟步行距离(6MWD)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)及改善心力衰竭生活质量量表(MLHFQ)评分。结果:共纳入22项随机对照研究,1 988例患者,其中芪苈强心组1 002例,对照组986例,平均随访6.5个月。与对照组相比,芪苈强心组BNP水平降低(均值差=-194.97,95%CI:-287.95^-101.99),LVEF增加(均值差=5.24,95%CI:3.38%~7.11%),LVEDD减小(均值差=-0.94,95%CI:-1.46^-0.43),6MWD增加(均值差=53.81,95%CI:46.9~60.73),MLHFQ评分降低(均值差=-8.11,95%CI:-10.23^-6.0),不良事件发生率显著降低(比值比=0.44,95%CI:0.25~0.79,P<0.01)。结论:芪苈强心胶囊对于改善CHF患者心功能和生活质量是安全有效的。
Objective: To evaluate the efficacy and safety of qiliqiangxin capsule in treating the patients with chronic heart failure(CHF).Methods: We searched the databases of Pubmed, EMBASE, Web of science, Wanfang, VIP, CBM and CNKI from 2007-01 to 2017-03 to collect the randomized trials of qiliqiangxin capsule in treating CHF patients. Blood levels of NT-pro BNP, 6 minutes walkingdistance(6 MWD), left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD) and Minnesota living with heart failure questionnaire(MLHFQ) scores were compared between qiliqiangxin capsule treated patients and control patients.Results: A total of 22 randomized trials were finally enrolled which included 1 988 patients by 2 groups: Qiliqiangxin capsule group, n=1 002 and Control group, n=986. Patients were followed-up at the mean 6.5 months. Compared with Control group, Qiliqiangxin capsule group had decreased blood level of NT-pro BNP, weighted mean difference(WMD)=-194.97, 95% CI(-287.95 to-101.99), increased LVEF, WMD=5.24, 95% CI(3.38-7.11), reduced LVEDD, WMD=-0.94, 95% CI(-1.46 to-0.43), elevated 6 MWD, WMD=53.81, 95% CI(46.9-60.73), lower MLHFQ score WMD=-8.11, 95% CI(-10.23 to-6.0) and less adverse events occurrence, OR=0.44, 95% CI(0.25-0.79), P0.01.Conclusion: Qiliqiangxin capsule was safe and effective for improving the cardiac function and quality of life in CHF patients.
出处
《中国循环杂志》
CSCD
北大核心
2018年第1期96-101,共6页
Chinese Circulation Journal
关键词
心力衰竭
利钠肽
脑
芪苈强心胶囊
Heart failure
Natriuretic peptide, brain
Qiliqiangxin capsule